Business profile & competitive position
Insulet Corp. operates in the Healthcare sector, specifically the Medical - Devices industry. The company develops, manufactures, and sells proprietary tubeless continuous insulin delivery systems, primarily the Omnipod platform, for people with insulin-dependent diabetes. Its product family includes the Omnipod 5 automated insulin delivery (AID) system, the Omnipod DASH insulin management system, and the Classic Omnipod, which Insulet is phasing out. It also manufactures pods for Amgen’s Neulasta Onpro kit.
Omnipod products are available in 25 countries, and 86% of 2025 global Omnipod product sales flowed through intermediaries. On the manufacturing side, Insulet runs highly automated plants in Acton, Massachusetts and Johor, Malaysia, and is investing in a third plant in Costa Rica. That footprint, combined with a net margin of 13.4% and an ROE of 29.5%, points to a focused medical-device franchise with meaningful pricing power and efficient capital conversion. The gap between the 13.4% net margin and the 29.5% ROE suggests the company is amplifying equity returns through leverage or asset turnover rather than pure margin expansion.
Financial posture
At a recent price of $150.13, Insulet carries a market capitalization of $10.4 billion and trades at a P/E ratio of 24.4. That is a valuation that embeds meaningful growth expectations relative to the broader market. The company is solidly profitable, with a net margin of 13.4% and an ROE of 29.5%. Its beta is 1.06, meaning the stock has historically moved in line with the broad market rather than showing outsized volatility.
The combination of a 24.4 P/E, a 13.4% net margin, and a 29.5% ROE creates a more nuanced picture than the P/E alone: the market is paying a premium for above-average returns on equity, not just for profitability. Because no debt figure was supplied in the current data, investors should verify whether the elevated ROE is supported by sustainable leverage, operating efficiency, or both. Overall, the financial posture is that of a premium-valued, profitable device company with market-like sensitivity.
Strategic priorities & outlook
Insulet’s most recent 10-K filing outlines a clear near-term operational agenda. The company wants to build consumer awareness of Omnipod’s features and benefits that simplify diabetes management, strengthen physician support with clinical evidence and data insights, and provide payors with clinical and economic justifications for Omnipod’s unique value.
On the product roadmap, Insulet is improving Omnipod 5, integrating it with Libre 3 Plus, developing Omnipod 6, and planning to start the U.S. IDE pivotal study for a fully closed-loop AID system for type 2 diabetes in 2026. The filing also notes that Classic Omnipod is being phased out. To support that growth, Insulet is scaling capacity through automated manufacturing in Acton and Johor, plus the planned Costa Rica facility, and its workforce grew 38% to approximately 5,400 full-time employees as of December 31, 2025. The strategic message is one of clinical differentiation, reimbursement muscle, product-cycle refresh, and manufacturing expansion.
Macro & geopolitical exposure
As a Healthcare/Medical - Devices company, Insulet’s exposures map closely to the typical risk profile of the device industry. FDA regulation, reimbursement decisions by Medicare/Medicaid, and private payor coverage policies can materially affect demand and pricing. With products sold in 25 countries, currency translation and overseas regulatory approvals are ongoing considerations; a stronger U.S. dollar, for instance, can compress the reported value of international revenue.
The global manufacturing footprint in Massachusetts, Malaysia, and Costa Rica also exposes the company to trade policy, tariffs, and supply-chain logistics. Medical devices are generally non-discretionary, so demand is less tied to consumer cyclicality than to public-health budgets, insurance coverage, and diabetes prevalence. Those macro forces are more relevant to the investment case than near-term economic growth alone.
Recent developments
The most recent news cluster centers on the November 2026 earnings cycle and surrounding investor activity. On November 4, 2026, MarketBeat published “What Insulet (PODD) Said on Its Q3 Earnings Call,” and Seeking Alpha released the Q3 2026 earnings call transcript. On November 8, 2026, defenseworld.net reported that Chicago Partners Investment Group LLC purchased PODD shares. On November 9, 2026, Insulet announced via BusinessWire a World Diabetes Day campaign titled “Give Yourself the Freedom to,” encouraging people with diabetes to prioritize their well-being. These headlines underscore a mix of post-earnings transparency, institutional accumulation, and consumer-facing brand messaging.
Earnings behavior & post-earnings drift
Insulet’s earnings record has been remarkably consistent. Over the last eight reported quarters, the company has beaten estimates in every quarter, an 8/8 (100%) beat rate, with an average earnings surprise of 17.9%. The average 5-day price move in the trading days after those reports has been 1.13%, classified as “up.”
Looking at the last four reported quarters, however, shows that headline beats do not always drive immediate price gains. On November 4, 2026, actual EPS was $1.99 versus an estimate of $1.59, a 25.2% surprise, but the stock fell 5.39% the next day and posted a 0% five-day drift. The August 5, 2026 quarter delivered $1.66 versus $1.47, a 12.9% surprise, and the stock rose 4.53% the next day and 8.85% over the following five days. The May 6, 2026 quarter saw actual EPS of $1.42 versus $1.19, a 19.3% surprise, with a 6.03% next-day pop but a -1.61% five-day drift. The February 18, 2026 quarter produced $1.55 versus $1.47, a 5.4% surprise, yet the stock dropped 3.48% the next day and drifted -3.86% over the next week.
That pattern suggests the unofficial consensus already assumes Insulet will beat expectations, which can set a high bar for the stock’s reaction even when results exceed published estimates. The next scheduled report is February 17, 2027, before the open, with a consensus EPS estimate of $1.79.
For a deeper dive into how sell-side institutions are interpreting Insulet’s manufacturing ramp, the Omnipod 5 and Omnipod 6 product cycle, and the upcoming type 2 diabetes IDE study, consider reviewing the full institutional verdict and analyst estimates rather than relying on headline numbers alone.
Frequently Asked Questions
What is Insulet’s core business?
Insulet Corporation develops, manufactures, and sells tubeless continuous insulin delivery systems under the Omnipod brand, primarily for people with insulin-dependent diabetes. Its products include the Omnipod 5 automated insulin delivery system, the Omnipod DASH insulin management system, and the Classic Omnipod, which is being phased out. It also produces pods for Amgen’s Neulasta Onpro kit.
How has Insulet performed relative to earnings estimates?
Over the last eight reported quarters, Insulet has beaten earnings estimates every time, producing a 100% beat rate and an average earnings surprise of 17.9%. Despite the consistent beats, price reactions have been mixed: for example, the November 2026 quarter delivered a 25.2% EPS surprise, but the stock fell 5.39% the next day.
What near-term priorities does Insulet highlight in its 10-K?
The company’s stated priorities include building consumer awareness, strengthening physician support with clinical evidence, providing payors with value justifications, improving Omnipod 5, integrating it with Libre 3 Plus, developing Omnipod 6, and starting the U.S. IDE pivotal study for a fully closed-loop AID system for type 2 diabetes in 2026.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-11-04 | $1.99 | $1.59 | +25.2% | -5.39% | null% |
| 2026-08-05 | $1.66 | $1.47 | +12.9% | +4.53% | +8.85% |
| 2026-05-06 | $1.42 | $1.19 | +19.3% | +6.03% | -1.61% |
| 2026-02-18 | $1.55 | $1.47 | +5.4% | -3.48% | -3.86% |
| 2025-11-06 | $1.24 | $1.14 | +8.8% | - | - |
| 2025-08-07 | $1.17 | $0.92 | +27.2% | - | - |
Previous PODD editions
Get the institutional verdict on PODD
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the PODD verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.